drug

Cholecalciferol

MeSH D002762
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by NYU Langone Health
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Influence of Vitamin D Supplementation on Serum BDNF Level and Cognitive Function in Schizophrenia
NCT03284294Phase 3Unknown
Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia
NCT02197286Phase 2Withdrawn

KOLs & investigators

1
James D Clelland

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
NYU Langone Health
company
trial
Influence of Vitamin D Supplementation on Serum BDNF Level and Cognitive Function in Schizophrenia
PHASE3
trial
Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia
PHASE2
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
Schizoaffective Disorder
indication
KOL
James D Clelland
KOL score —
person